Search
Mirum Pharmaceuticals Inc
MIRMAdd to Watchlist
107.130USD
+5.090+4.99%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
5.56BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Mirum Pharmaceuticals Inc is 8.86, ranking 7 out of 157 in the Pharmaceuticals industry. The average price target is 91.00, with a high of 95.00 and a low of 80.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
147.682
Target Price
+37.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Mirum Pharmaceuticals Inc
MIRM
14
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Mirum Pharmaceuticals Inc's expected revenue for the next quarter?
Mirum Pharmaceuticals Inc's expected revenue is 166.12M.
What is Mirum Pharmaceuticals Inc's price target?
Analysts forecast that Mirum Pharmaceuticals Inc's price target is USD 91.00, with the highest forecast at USD 95.00 and the lowest forecast at USD 80.00.
How have Mirum Pharmaceuticals IncMIRM's recent earnings per share performed?
The market expectation was USD -13.43, while Mirum Pharmaceuticals IncMIRM's earnings per share (EPS) for the previous quarter was USD -0.11. EPS for the next quarter is expected at USD -0.69.
What is the analyst rating for Mirum Pharmaceuticals Inc?
Based on the ratings of Mirum Pharmaceuticals Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
